Study summary
A complement-blocking pill halved the rate of kidney function loss over two years
21.4%reached kidney failure or major decline, vs 33.5% with placebo
What was tested
Iptacopan, a pill that blocks factor B in the alternative complement pathway (part of the immune system that damages the kidney filters), against placebo, for IgA nephropathy with high protein in the urine.
What they found
- Kidney function (eGFR) declined 3.10 per year vs 6.12 with placebo.
- Kidney failure or a sustained 30% loss of function occurred in 21.4% vs 33.5% (hazard ratio 0.57).
- Serious infections were more common (6.7% vs 2.1%).
What it means
The first IgA nephropathy drug to show slower loss of kidney function over two years, not just less protein in the urine.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.